Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
on September 28, 2011
ANAHEIM, Calif., Sept. 19, 2011 /PRNewswire via COMTEX/ -- Questcor
Pharmaceuticals, Inc. (QCOR) announced today that executive management will
present at the Jefferies Global Healthcare Conference to be held September 27-28,
2011 in London. Don M. Bailey, President and Chief Executive Officer, is
scheduled to present an overview of the Company on Wednesday, September 28, 2011
at 8:00 a.m. BST. Mr. Bailey will utilize the Company's investor presentation
that was previously filed with the U.S. Securities and Exchange Commission on
September 12, 2011 under Form 8-K.
"This will be our first investor conference in Europe," commented Mr. Bailey.
"While Questcor's primary product, H.P. Acthar? Gel (repository corticotropin
injection), is not approved for marketing outside of the United States, we look
forward to discussing Questcor with European investors as we continue to
experience growth of both prescriptions and net sales in our multiple sclerosis
exacerbation and nephrotic syndrome markets."
A live webcast and subsequent archived replay of the presentation will be
accessible at ir.questcor.com. The replay will be available for
ninety days after the event.
About Questcor
Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary
product helps patients with serious, difficult-to-treat medical conditions.
Questcor's primary product is H.P. Acthar? Gel (repository corticotropin
injection), an injectable drug that is approved by the FDA for the treatment of
19 indications. Of these 19 indications, Questcor currently generates
substantially all of its net sales from three indications: the treatment of acute
exacerbations of multiple sclerosis in adults, the treatment of nephrotic
syndrome, and the treatment of infantile spasms in children under two years of
age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a
diuresis or a remission of proteinuria in the nephrotic syndrome without uremia
of the idiopathic type or that due to lupus erythematosus." Questcor is also
exploring the use of Acthar to treat systemic lupus erythematosus, for which
Acthar is approved as both a maintenance therapy and to treat exacerbations.
Questcor is also exploring the possibility of developing markets for other
on-label indications and the possibility of pursuing FDA approval of additional
indications not currently on the Acthar label where there is high unmet medical
need. For more information, please visit questcor.com.
Note: Except for the historical information contained herein, this press release
contains forward-looking statements that have been made pursuant to the Private
Securities Litigation Reform Act of 1995. These statements relate to future
events or our future financial performance. These statements are only
predictions. Actual events or results may differ materially. Factors that could
cause or contribute to such differences include, but are not limited to, the
following:
Our reliance on Acthar for substantially all of our net sales and profits;
Reductions in vials used per prescription resulting from changes in treatment
regimens by physicians or patient compliance with physician recommendations;
Our ability to generate revenue from sales of Acthar to treat on-label
indications associated with NS;
Regulatory changes or other policy actions by governmental authorities and other
third parties in connection with U.S. health care reform or efforts to reduce
federal and state government deficits;
Our ability to receive high reimbursement levels from third party payers;
An increase in the proportion of our Acthar unit sales comprised of
Medicaid-eligible patients and government entities;
Our ability to effectively manage our growth, including the expansion of our NS
selling effort;
Other risks discussed in Questcor's annual report on Form 10-K for the year ended
December 31, 2010, and other documents filed with the Securities and Exchange
Commission.
The risk factors and other information contained in these documents should be
considered in evaluating Questcor's prospects and future financial performance.
Questcor undertakes no obligation to publicly release the result of any revisions
to these forward-looking statements, which may be made to reflect events or
circumstances after the date of this release. |
